DelveInsight’s, “Diabetes Pipeline Insights, 2023,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including Diabetes clinical trials and nonclinical stage products. It also covers the Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Diabetes pipeline report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Diabetes NDA approvals (if any), and product development activities comprising the technology, Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Diabetes Pipeline Insight Report
- DelveInsight’s Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
- The leading Diabetes Companies includes Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
- Promising Diabetes Pipeline Therapies includes LY2963016, Drug: Lantus, Drug: OAMs, Drug: insulin glargine + exenatide + preexisting metformin, Drug: insulin glargine + sitagliptin + preexisting metformin, Drug: insulin glargine + preexisting metformin, ORMD-0801, Cotadutide, and others.
- The Diabetes companies and academics are working to assess challenges and seek opportunities that could influence R&D Multiple myeloma. The Diabetes pipeline therapies under development are focused on novel approaches to treat/improve Diabetes.
To explore more information on the latest breakthroughs in the Diabetes Pipeline treatment landscape of the report, click here @ Diabetes Pipeline Outlook
Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or alternatively, when the body cannot effectively use the insulin it produces. The vast majority of Diabetes can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease is characterized by a lack of insulin production by the pancreas. Type 2 diabetes occurs when body becomes resistant to insulin, and sugar builds up in the blood. About 90% of people with diabetes around the world have type 2. It is largely the result of excess body weight and physical inactivity. Diabetes can cause a heart attack, stroke, blindness, kidney disease, nerve damage, and other serious health problems.
Diabetes Emerging Drugs Profile
Enavogliflozin – Daewoong
Enavogliflozin (DWP 16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. The molecule is in phase-3 clinical trials for type-2 diabetic treatment. Enavogliflozin demonstrates the lowering of blood sugar and safety in diabetic patients in phase 2 clinical trials.
Golimumab – Janssen Biotech
Golimumab is a human IgG1 monoclonal antibody, derived from immunizing genetically engineered mice with human TNFα. It inhibits soluble and transmembrane forms of TNF-α by binding to their specific receptors and blocking in consequence their bioactivity. It is currently under Phase II development for the treatment of Type 1 diabetes mellitus.
For further information, refer to the detailed Diabetes Unmet Needs, Diabetes Market Drivers, and Diabetes Market Barriers, click here for Diabetes Ongoing Clinical Trial Analysis
Diabetes Pipeline Therapies and Key Companies
- Daewoong Tradipitant: LY2963016
- Janssen Biotech: Lantus
- Zealand Pharma: OAMs
- Provention Bio: insulin glargine
- BioRestorative Therapies: exenatide
- Elevian: preexisting metformin
- Kamada: insulin glargine
- Adocia: sitagliptin
- Oramed Pharmaceuticals: preexisting metformin
- ImCyse: insulin glargine
- Histogen: preexisting metformin
- Novo Nordisk: ORMD-0801
- Enthera: Cotadutide
Diabetes Pipeline Therapeutic Assessment
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Route of Administration
- ·Molecule Type
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Request a sample and discover the recent advances in Diabetes Ongoing Clinical Trial Analysis and Medications, click here @ Diabetes Treatment Landscape
Scope of the Diabetes Pipeline Report
- Coverage- Global
- Diabetes Companies- Daewoong Tradipitant, Janssen Biotech (JNJ: NYSE), Zealand Pharma (NYSE: ZLDPF), Provention Bio (NYSE: PRVB), BioRestorative Therapies (NYSE: BRTX), Elevian, Kamada (NYSE: KMDA), Adocia (NYSE: ADOC), Oramed Pharmaceuticals (NYSE: ORMP), ImCyse, Histogen (NYSE: HSTO), Novo Nordisk (NYSE: NVO), Enthera Bio (NYSE: ENTX), ActoBio Therapeutics, Japan Tobacco (NYSE: JAPAF), Avotres, and others.
- Diabetes Pipeline Therapies- LY2963016, Drug: Lantus, Drug: OAMs, Drug: insulin glargine + exenatide + preexisting metformin, Drug: insulin glargine + sitagliptin + preexisting metformin, Drug: insulin glargine + preexisting metformin, ORMD-0801, Cotadutide, and others.
- Diabetes Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Diabetes Market Drivers and Diabetes Market Barriers, click here @ Diabetes Unmet Needs and Analyst Views
Table of Content
- Executive Summary
- Diabetes: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Diabetes – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Diabetes Collaboration Deals
- Late Stage Products (Phase III)
- Enavogliflozin: Daewoong
- Mid Stage Products (Phase II)
- Golimumab: Janssen Biotech
- Early Stage Products (Phase II/I)
- IMCY-0098: ImCyse
- Pre-clinical and Discovery Stage Products
- ENT-001: Enthera
- Drug profiles in the detailed report…..
- Inactive Products
- Diabetes Key Companies
- Diabetes Key Products
- Diabetes- Unmet Needs
- Diabetes- Market Drivers and Barriers
- Diabetes- Future Perspectives and Conclusion
- Diabetes Analyst Views
- Diabetes Key Companies
Got Queries? Find out the related information on Diabetes Mergers and acquisitions, Diabetes Licensing Activities @ Diabetes Emerging Drugs, and Recent Trends
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States